Superinfections in patients treated with Teicoplanin as anti-SARS-CoV-2 agent
01 Pubblicazione su rivista
Ceccarelli G., Alessandri F., Oliva A., Dell'Isola S., Rocco M., Ruberto F., Pugliese F., d'Ettorre G., Venditti M.
DOI: 10.1111/eci.13418
ISSN: 0014-2972
We read with interest the paper by Giacobbe et al. estimating a cumulative risk of developing at least one bloodstream infection (BSI) episode (largely due to Gram‐positive pathogens) of almost 50% after 30 days at risk in severe COVID‐19 patients. (2) Similarly, Somers et al. reported an increased risk to develop bacterial superinfections, principally represented by Staphylococcus aureus ventilatory associated pneumonia (VAP), in critically ill patients infected with SARS‐CoV‐2 and treated with Tocilizumab.
Acinetobacter Infections Aged Anti-Bacterial Agents Antibodies Monoclonal Humanized Azithromycin bacteremia Candidemia COVID-19 enzyme inhibitors Female Gram-negative bacterial infections Humans Italy Klebsiella Infections male methicillin-resistant staphylococcus aureus Middle Aged pneumonia Ventilator-Associated Protective Factors Pseudomonas Infections respiration artificial SARS-CoV-2 Staphylococcal Infections superinfection teicoplanin